Skip to main content

Table 5 Univariate/Multivariate Analysis of OS in HER2-Positive Advanced Breast Cancer Patients With T-DM1 Treatment

From: High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine

Variables

Univariate

Multivariate

HR(95% CI)

P

HR(95% CI)

P

LDH

4.368(2.010–9.493)

< 0.001

  

dNLR

3.756(1.843–7.657)

< 0.001

  

LNI

LNI(1)

2.498(1.069–5.836)

0.035

2.063(0.818–5.203)

0.125

LNI(2)

16.209(5.837–45.011)

< 0.001

13.354(4.570–39.025)

< 0.001

Age

1.373(0.591–3.186)

0.461

  

ECOG PS

2.587(1.302–5.140)

0.007

3.471(1.593–7.562)

0.002

Menstrual status

0.820(0.379–1.774)

0.614

  

Thrombocytopenia CTCAE grades

1.515(0.718–3.197)

0.275

  

Treatment lines

1.062(0.524–2.152)

0.869

  

Liver metastases

1.574(0.790–3.136)

0.197

  

Brain metastasis

1.095(0.451–2.658)

0.841

  

HER2 status

0.172(0.063–0.470)

0.001

0.166(0.051–0.542)

0.003

HR status

1.382(0.700–2.729)

0.352

  

Number of metastatic sites

1.360(0.560–3.300)

0.497

  

Prior surgery

0.761(0.263–2.202)

0.614

  

Trastuzumab plus pertuzumab

0.812(0.378–1.744)

0.593

  

Anti-HER2 treatment

0.765(0.315–1.857)

0.554

  

BMC status

0.761(0.263–2.202)

0.614

  

LDH changing trend

Down

0.863(0.399–1.868)

0.709

0.539(0.234–1.240)

0.146

Steady

0.303(0.110–0.840)

0.022

0.235(0.079–0.701)

0.009

dNLR changing trend

Down

1.139(0.523–2.480)

0.743

  

Steady

0.615(0.256–1.477)

0.277

  
  1. (Annotation: LDH ≤ 244 U/L, dNLR≤1.985, LNI(0), Age < 60 year, ECOG PS < 1, Premenopauseas, Thrombocytopenia CTCAE grades ≤2, Treatment lines < 2、No brain metastasis, No hepatic metastases, Her2(IHC2 + , FISH+), HR(−), Metastatic sites ≤2, No prior surgery,No trastuzumab plus pertuzumab treatment, No anti-HER2 treatment, de novo BMC,LDH uptrend, dNLR uptrend as references)